Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Get Alerts ARDX Hot Sheet
Join SI Premium – FREE
FREMONT, Calif., Feb. 17, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. ET on Wednesday, Feb. 24, 2021.
To access the webcast of Ardelyx's presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the fireside chat will be available on the Ardelyx website for 60 days following the presentation.
About Ardelyx, Inc.Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-301229549.html
SOURCE Ardelyx
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CGTN: 5 years on, President Xi reemphasizes China's western region development strategy
- SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Rivian Automotive, Inc. with Losses to Contact the Firm
- FORVIA SUCCESSFULLY PRICES AN ADDITIONAL €200 MILLION OF 5.500% SENIOR NOTES DUE 2031
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
PDUFA, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!